HBV, Primary Liver Cancer
Conditions
Brief summary
In summary, with the help of single-cell sequencing technology, this study aims to focus on elucidating the influence of HBV-induced hepatocellular carcinoma cell metabolic changes on microenvironment remodeling. With the help of hepatocellular carcinoma microenvironment changes, this study provide a more accurate diagnosis and treatment method for HBV-induced hepatocellular carcinoma.
Interventions
DIAGNOSTIC_TESTHBV DNA Sequencing
Clinical surgical specimens were obtained, cleaned briefly and transported to the laboratory. Single-cell suspension preparation and blood cell separation were performed, single-cell sorting suspension was prepared and put on the machine, sorting and library construction were performed, and mRNA sequencing adaptor was docked. Single cell data analysis. Based on the findings of single cell analysis, functional verification tests of tumor immune microenvironment cell groups and functional changes of tumor cells were designed.
Sponsors
Fubing Wang
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with primary liver cancer (hepatocellular carcinoma (HCC)), with evidence of histological or cytological diagnosis, or with HCC meeting conventional clinical diagnostic criteria. * Both sexes, aged 18-80 years old * The results of HBVDNA test were in line with the inclusion criteria * The patient had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST V1.1) * Agreed to comply with the study protocol for treatment and follow-up, agreed to provide clinicopathological and follow-up data required by the study, and agreed to use the study data for subsequent research and product development
Exclusion criteria
* Other malignant tumors; * Patients with severe organic diseases do not meet the requirements of infectious liver cancer in this study; * Suffering from mental illness cannot guarantee the compliance of this study; * Previous recipients of any cell or organ transplantation; * Received local regional liver therapy (including various ablations, percutaneous ethanol or acetic acid injections, high-intensity focused ultrasound, transarterial embolization, chemotherapy, or chemoembolization plus embolization) within 14 days prior to study treatment initiation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| single cell RNA sequencing | within 4 hours after the sample was submitted for examination | 10x genomics chromium 3' sequencing |
| Biochemical index detection | within 4 hours after the sample was submitted for examination | HbsAg (IU/mL) \\HbsAb (mIU/mL)\\HbeAg\\HbeAb\\HbcAb |
| HBV DNA copy number | within 24 hours after the sample was submitted for examination | HBV DNA (IU/mL) |
Countries
China
Contacts
Primary ContactFubing Wang, Doctor
Outcome results
None listed